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INTRODUCTION 
 
 
The children undergoing open-heart surgery are likely to have 
major blood loss due to surgical interventions performing on major 
vascular structures as well as the coagulation abnormalities that 
accompany extracorporeal techniques. Certain characteristics are unique 
to paediatric patients with congenital heart disease undergoing heart 
surgery, that makes them prone to excessive bleeding and transfusion of 
blood and blood products(1). They are: 
• Decreased levels of coagulation factors compared with 
normal children of the same age group. 
• Hemodilution resulting from high priming volume relative 
to small blood volume. 
• Delayed hepatic maturation secondary to poor organ 
perfusion. 
• Complex operative procedures requiring long duration of 
cardiopulmonary bypass. 
• Multiple extra cardiac suture lines. 
• Deep hypothermic circulatory arrest. 
The use of aprotinin in children undergoing cardiopulmonary bypass  
attenuates the activation of the coagulation and fibrinolytic systems, preserves 
platelets function and reduces systemic inflammatory responses. Improved 
clinical outcomes have been consistently demonstrated in children undergoing 
primary and repeat sternotomies in aprotinin recipients. Many studies have 
demonstrated benefits in terms of(2,3,4) -  
• Significant reduction in chest tube drainage 
• Time to skin closure 
• Postoperative transfusion requirements 
• Decreased requirements of banked blood and donor 
exposures(4,5) 
• Substantial savings in cost(4,5)    
These clinical outcomes create a strong argument for the routine 
administration of aprotinin in paediatric cardiac operations undergoing 
cardiopulmonary bypass. Aprotinin is a potent part of an anesthesiologist 
arsenal when dealing with children undergoing cardiopulmonary bypass and its 
cost effective improvement of clinical outcomes justifies its consideration 
when planning the management strategy of these children. 
                                                                
 
AIM OF THE STUDY 
 
 
        The purpose of the study was to assess the efficacy and use of 
aprotinin in paediatric open heart surgeries by comparing the time 
interval from protamine administration to skin closure, the volume of 
blood loss (ml/kg) in chest drain after 24 hours, and the volume of blood 
and blood products (ml/kg) transfused postoperatively with that of 
control group(4,8). 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
APROTININ 
Introduction 
Cardiopulmonary bypass is associated with a systemic 
inflammatory  response, a spectrum of pathophysiologic changes ranging 
from mild organ dysfunction to multisystem organ failure. Complications 
include coagulation disorders (bleeding diathesis, hyperfibrinolysis) 
from platelet defects and plasmin activation, as well as pulmonary 
dysfunction from neutrophil sequestration and degranulation. Diverse 
injuries are a consequence of multiple inflammatory mediators 
(complement, kinins, kallikrein, cytokines). Both plasmin and kallikrein 
amplify the inflammatory response by activating components of the 
contact activation system. High dose of aprotinin, a serine protease 
inhibitor approved for reducing blood loss and transfusion requirements 
in cardiopulmonary bypass, inhibits kallikrein and plasmin, resulting in 
suppression of multiple systems involved in the inflammatory response. 
Overall, evidence indicates that aprotinin attenuates the systemic 
inflammatory response associated with cardiopulmonary bypass. 
 Historical perspective 
1960 - Aprotinin was first used in man 
1987 - First clinical study of high dose regime in 
cardiac surgery 
1993 - Approved by FDA for use during cardiac 
surgery  
1999 - Meta-analysis suggests little clinical efficacy 
difference between aprotinin and aminocaproic acid 
2004 - Two small studies report reduced bleeding in 
CABG patients on anti-platelet therapy  
2005 - Meta-analysis suggests aprotinin is safe in 
paediatric surgery 
 
Mechanism of action 
Aprotinin is a basic polypeptide, 58 amino acid residues long and 
of bovine origin(9), inhibits a wide variety of serum proteases. The main 
mechanism of action of aprotinin is inhibition of plasmin. The high-dose 
aprotinin regimen also inhibits kallikrein, produced from prekallikrein 
during activation of factor XII by the artificial surfaces of the bypass 
equipment and the exposed surfaces of surgically cut vessels. 
The antiplasmin action of aprotinin coupled with inhibition of 
kallikrein(10) provides a significant antifibrinolytic  and anti-
inflammatory effect. By inhibiting kallikrein, aprotinin reduces the 
activation of complement(10), the angiotensin system and bradykinin. 
Antifibrinolytic action 
Fibrin clots are formed at the sites of surgical incision and function 
to maintain hemostasis during surgery. Activation of the fibrinolytic 
pathway converts the zymogen plasminogen to the protease plasmin. 
Plasmin degrades fibrin plugs by proteolytically digesting fibrin. In 
addition to generating proinflammatory fibrin split products, plasmin 
amplifies the inflammatory response by directly activating FXII. 
Members of the kinin-kallikrein pathway augment activation of the 
fibrinolytic pathway by ultimately upregulating plasmin levels. 
During and after CPB, D-dimer levels, a measurement of the amount of 
fibrin degraded by plasmin, were lower in patients receiving aprotinin therapy 
compared with controls, indicating that plasmin activity was attenuated in 
aprotinin patients (11). Reduced plasmin activity can be attributed to decreased 
plasmin production, direct inhibition of plasmin, or a combination of these two 
events. Observations suggest that reduced fibrinolytic activity resulting from 
aprotinin administration most likely results from direct binding and inhibition 
of plasmin, rather than inhibition of t-PA-mediated plasmin generation.   
Effect on platelets 
Fibrin degradation increases during CPB (12), and fibrin degradation 
products have been implicated in impaired fibrin formation, platelet 
dysfunction, and endothelial disruption resulting in capillary injury (13). 
Moreover, plasmin, a potent platelet inhibitor, reportedly degrades platelet 
adhesion receptors Gp Ib and Gp IIb in vitro(14,38), and by 50% in vivo during 
CPB (15), most notably at hypothermic temperatures(16). When added to washed 
platelets, plasmin reduces platelet membrane Gp Ib content by approximately 
75%(15). Taken together, these observations suggest that stimulation of the 
fibrinolytic system in CPB may result in decreased platelet function. Thus by 
its antifibrinolytic  activity, aprotinin preserves platelet function.  
Anti-inflammatory effect of aprotinin 
Aprotinin inhibits kallikrein and plasmin, resulting in suppression of 
multiple systems involved in the inflammatory response. Specifically, 
inhibition of factor XII, bradykinin, C5a, neutrophil integrin expression, 
elastase activity, and airway nitric oxide production are observed(39,40). Clinical 
correlates include reduced capillary leak, preserved systemic vascular resistance 
and blood pressure, and improved myocardial recovery following ischemia.  
Kinin-kallikrein pathway 
During CPB, autoactivation of the inert factor XII (FXII), when 
bound to anionic surfaces, yields factor XIIa (FXIIa) and factor XIIf 
(FXIIf). In the presence of high molecular weight kininogen (HMWK), 
FXIIa converts prekallikrein to kallikrein, and in a positive feedback 
loop, kallikrein and FXIIa enzymatically activate additional FXII(17). 
Kallikrein also cleaves surface-bound HMWK to liberate bradykinin 
(BK), a potent vasodilator that promotes smooth muscle contraction and 
capillary permeability(17). Products of the kinin pathway also participate 
in the cellular inflammatory response by directly stimulating neutrophils. 
Neutrophil superoxide and hydrogen peroxide formation are reportedly 
upregulated in the presence of kallikrein (18).  
Overall, evidence indicates that aprotinin attenuates the systemic 
inflammatory response associated with cardiopulmonary bypass.  
Pharmacokinetics 
Plasma aprotinin concentration decrease rapidly after intravenous 
administration because of redistribution to peripheral tissues(34). During 
elimination phase, which is primarily renal, accumulation of aprotinin 
takes place in proximal tubular epithelial cells of the kidneys, where the 
drug may be gradually broken down over several days(37). Approximately 
80% of an injected dose of aprotinin can be localized in kidneys, 4 hours 
after injection. 
Clearance of aprotinin is 35.5 ml/min and the volume of 
distribution at steady state is 26.5 litres (34). The elimination half time of 
aprotinin after administration of a single intravenous dose is 7 hours. 
Dosage  
The enzymatic activity of aprotinin is generally expressed in 
kallikrein inactivator units (KIU). One KIU is defined as the amount of 
aprotinin that decreases the activity of 2 biologic kallikrein units by 
50%. 
One mg of aprotinin is equivalent to 7143 KIU. Effective 
inhibition of plasmin requires a plasma concentration of  50 KU/ml and 
200 KIU/ml of aprotinin to inhibit plasma kallikrein(21,22). 
Dosage regimens 
A wide range of dosing regimen has been used in adults and 
children. The classical adult dosage regimen consists of 2x106 KIU 
loading dose administrated over a 20 min after a test dose, after 
induction of anaesthesia, followed by a continuous infusion of 6,00,000 
KIU/hour until the patient is transferred to the ICU. In addition, 2x 106 
KIU is added to pump to overcome the dilution effect(19,20). 
In paediatric population, varying dosing regimens have been used 
based on body weight and body surface area (BSA). With weight-based 
regimens loading doses have ranged from 15000 to 50,000 KIU/kg and 
infusion have ranged from 0 to 30,000 KIU/kg/hour. Pump priming 
doses usually have been the same as the child’s loading dose(4,7,15,23). 
Based on the body surface area, loading and pump prime doses 
have ranged from 120 to 240 mg/m2 in smaller children with 250 to 280 
mg/m2  being used in children whose BSA exceeds 1.16m2  (8,24,25). 
Infusion range varies from 28 to 56 mg/m2/hour with 70 mg/m2/hour 
being given to the larger children. 
Interaction with heparin 
Adequate heparinisation is usually maintained by monitoring 
activated clotting time (ACT) values of > 400 seconds. Aprotinin 
inhibits contact activation of the intrinsic clotting system and therefore 
prolong the results of coagulation assays such as celite ACT. Aprotinin 
does not have an inhibitory effect on extrinsic clotting cascade, so that 
heparin level must always be sufficient to prevent the clot formation. 
Maintaining the celite ACT above 400 to 450 seconds may not be a 
reliable indicator of adequate heparinisation. The current 
recommendation regarding monitoring of anticoagulation in the presence 
of aprotinin is to maintain celite ACT values at > 750 seconds during 
CPB or to use kaolin ACT, heparin – protamine titration test(29). The 
kaolin ACT adsorbs about 98% of aprotinin and any intrinsic 
antithrombin effect that aprotinin has is therefore mitigated. It is 
recommended to use kaolin ACT and keep the length of ACT times the 
same as if aprotinin was not being used(26,27,28). 
Indications 
1. Reduction of blood loss, particularly hyperfibrinolytic 
hemorrhage 
2. Traumatic, hemorrhagic, pancreatogenic and endotoxic 
shock. 
3. Fat-embolism syndrome 
4. Acute pancreatitis  
Contraindication 
Aprotinin is contraindicated in patients who have demonstrated 
hypersensitivity. 
THERAPEUTIC USE OF APROTININ 
Reoperations 
Patients having repeat surgery through prior median stermotomy 
are known to be at a greater risk for perioperative bleeding and therefore 
require more homologous blood transfusion. Aprotinin has significantly 
reduced the duration of procedure, perioperative blood loss and 
postoperative transfusion. Benefits were shown in pediatric patients 
undergoing reoperations(4,5,6) and complex surgical intervention(7). 
Primary myocardial revascularisation 
Aprotinin is effective in terms of reduction in number of patients 
receiving donor blood and the total donor blood transfusions. Aprotinin 
recipients have a significantly drier operative field. The efficacy of 
aprotinin in counter balancing the increased risk of perioperative 
hemorrhage in CABG patients pretreated with aspirin, without increasing 
risk of myocardial infarction has been demonstrated. 
Paediatric cardiac surgeries 
The studies have demonstrated benefits in terms of significant 
reduction in chest tube drainage, time to skin closure and transfusion 
requirements(21). There is a decreased requirement of banked blood and 
donor exposures. The anti inflammatory effects of aprotinin can be 
particularly important in paediatric population in attenuating the whole 
body inflammatory reaction. 
 
 
Other uses 
Aprotinin has also been found to be useful in major vascular 
surgery, acute pancreatitis ,patient with sepsis and endocarditis 
undergoing open-heart surgery, carcinoid syndrome, heart lung 
transplantation, and total hip replacement(35). There is significant 
decrease in total blood loss and the amount of blood transfused. 
Adverse effects 
a) Anaphylactic reactions 
An animal protein, aprotinin can cause anaphylaxis(30). The incidence is 
1 in 1000(31,32) patients and more in-patients reexposed to aprotinin. The 
anaphylactic reaction was defined as major changes from baseline within 10 
minute of aprotinin administration, of systolic blood pressure 20 percent or 
greater, heart rate 20 percent or greater, inspiratory pressure greater than 5cm 
of water or a skin reaction(33). Anaphylactic reactions were classified as mild 
(no intervention required), moderate (circulation restored within 15 min of 
reaction onset via use of vasopressors), or severe (longer-lasting circulatory 
depression and instability despite administration of vasopressors).This can be 
prevented by giving test dose of 10000 KIU intravenously and observed for 
hemodynamic changes.  
Preventive  measures for repeated use and/or allergic predisposition 
1. IV dose of H1 and H2 antogonists, 15 min prior to the first aprotinin 
dose. 
2. Subsequently 1ml (10000KIU) aprotinin IV with a 10 min observation 
period. 
3. After that a slow infusion of the loading dose can be started. 
In individual cases an anaphylactic response still can occur, in which 
case aprotinin should be stopped immediately. 
b) Renal dysfunction 
Renal dysfunction was defined as postoperative creatinine of atleast 
2mg/dl or an increase over preoperative baseline levels of atleast 0.7mg/dl . 
The use of high doses of aprotinin and hypothermia during cardiopulmonary 
bypass can produce dose-related transient and reversible increases in plasma 
creatinine concentrations. Aprotinin may cause afferent renovasoconstriction 
(36).         
REVIEW OF LITERATURE   
Miller et al 1998(4) 
They evaluated the haemostatic and economic effects of aprotinin 
in children undergoing reoperative cardiac procedures with 
cardiopulmonary bypass. Control, low-dose aprotinin, and high-dose 
aprotinin groups were established with 15 children per group. 
The control group received no aprotinin. The low-dose group 
received an aprotinin loading dose of 20,000 kallikrein inhibiting units 
(KIU) (2.8 mg) per kilogram before skin incision, 20,000 KIU/kg in the 
pump prime, and an infusion of 10,000 KIU/kg/h beginning with 
completion of the loading dose and terminating with skin closure. The 
high-dose group received a loading dose of 40,000 KIU/kg, 40,000 
KIU/kg in the pump prime, and an infusion of 20,000 KIU/kg/h after the 
loading dose to the end of skin closure.  
Platelet counts, fibrinogen levels, and thromboelastographic values 
at baseline and after protamine sulfate administration, number of blood 
product transfusions, and 6-hour and 24-hour chest tube drainage were 
used to evaluate the effects of aprotinin on postbypass coagulopathies. 
They concluded that in children undergoing reoperative cardiac surgical 
procedures, aprotinin is effective in attenuating postbypass 
coagulopathies, decreasing blood product exposure, improving clinical 
outcome, and reducing patient charges. 
Dietrich et al 1993(23) 
They studied the effect of high-dose aprotinin treatment on 
hemostatic activation during cardiopulmonary bypass in paediatric 
patients having cardiac operations. Sixty patients weighing less than 10 
kg undergoing cardiac operations for different types of congenital heart 
diseases were studied. 20 patients were treated with aprotinin 2 x 15,000 
KIU/kg, 20 patients with 2 x 30,000 KIU/kg, and 20 patients without 
aprotinin treatment served as the control group. Different split products 
of fibrinogen and/or fibrin and the fibrinolytic activity on fibrin plates 
were measured to assess fibrinolytic. 
They observed there is an attenuation of hemostatic activation 
during cardiopulmonary bypass with less plasmin formation and, because 
of inhibition of contact activation, less thrombin generation with 
aprotinin treatment. Thus the thrombotic-thrombolytic equilibrium is 
kept more balanced after cardiopulmonary bypass. This recommends 
high-dose aprotinin treatment  for paediatric patients undergoing cardiac 
operations. 
D’Errico et al 1996(5) 
They performed a prospective, randomized, placebo controlled, 
double-blind trial to assess the efficacy of and cost of aprotinin in 61 
children (median age 3.7 yr) undergoing reoperative open heart surgery 
(OHS). Three demographically similar groups were studied: large-dose 
aprotinin (ALD), small- dose aprotinin (ASD), and placebo (I’). Over the 
first 24 postoperative hours fewer patients in the aprotinin groups 
received packed red cells (ALD, 53%; ASD, 89%; and I’, 95%; P = 
0.00l), platelets (ALD, 32%; ASD, 50%; and P, 65%; P = 0.04), 60%; P 
= 0.003) than placebo patients. 
They showed that  aprotinin patients had fewer exposures to 
banked blood components (ALD, median 1 U; and ASD, median 2 U) 
than P (median 6 U; P = 0.00l), with no difference in overall 
complication rate.  In conclusion, aprotinin decreased the number of 
units of banked blood components used during the first 24 postoperative 
hours in reoperative pediatric OHS. Aprotinin thus decreases the risks 
associated with exposure to banked blood components and reduces 
hospital charges. 
Mossinger et al 2003(21) 
They conducted a double-blind,  randomized, and  placebo 
controlled study, to assess the efficacy of aprotinin in attenuating the 
hemostatic and inflammatory activation during cardiopulmonary bypass 
in 60 patients weighing less than10 kg. Secondary endpoints were the 
influence of aprotinin on the reduction of blood loss and allogeneic 
blood requirement, as well as postoperative oxygenation and length of 
mechanical ventilation. They concluded that  high-dose aprotinin 
effectively attenuated hemostatic activation and reduced blood loss and 
transfusion requirement in paediatric cardiac surgery.Postoperative 
ventilation was also shortened in the aprotinin group. 
Royston et al 1987(42) 
They studied the effect of aprotinin on need for blood transfusion 
after repeat open heart surgery . Of 22 patients undergoing repeat open-
heart surgery through a previous median sternotomy wound, 11 were 
randomised to receive  aprotinin in high dosage (about 700 mg 
intravenously from the start of anaesthesia to the end of operation, 
depending on the length of the surgical procedure). Their mean blood 
loss was 286 ml compared with 1509 ml in the 11 control patients (p 
<0.001), and mean haemoglobin losses were 8.3 g and 78 g, respectively 
(p < 0.001). Blood transfusion requirements were eightfold higher in the 
control group than in the aprotinin group, 7 of whom received only the 
single unit of their own blood taken before cardiopulmonary bypass. 
Mossinger et al 1998(43) 
They studied the characteristics of the hemostatic system in 
children undergoing cardiac operations and addressed the effect of 
aprotinin on hemostasis. Hemostatic parameters were measured in 96 
pediatric patients using three different doses of aprotinin. The high-dose 
group (group 1) received 30,000 KIU/kg (4.2 mg/kg) of aprotinin after 
induction of anaesthesia and an additional bolus of 30,000 KIU/kg (4.2 
mg/kg) into the pump prime. In the low-dose group (group 2), both the 
initial bolus and the pump-prime dose of aprotinin were halved to 15,000 
KIU/kg (2.1 mg/kg). Group 3 received the high dose with an additional 
bolus of aprotinin to the pump prime.  
They observed that plasma levels of aprotinin in both groups 1 and 
2 were lower than the 200 KIU/ml (0.03 mg/ml) value usually reached in 
adults with high-dose aprotinin treatment. Group 3 patients had levels 
greater than 200 KIU/ml (0.03 mg/ml) throughout the procedure. 
Biochemical indices of fibrinolysis (fibrin degradation products, D-
dimers) revealed significant and dose dependent inhibition at all three 
aprotinin concentrations. They concluded that the  inverse relationship 
between a small patient’s blood volume and the large pump-prime 
volume requires additional aprotinin to be added to the prime to achieve 
plasma levels sufficient to inhibit activation of the coagulation cascade. 
Dietrich et al 2001(33) 
This investigation examined the incidence of anaphylactic reactions in 
patients reexposed to aprotinin and the relation to preformed antiaprotinin 
immunoglobulin IgG and IgE antibodies. This prospective observational study 
evaluated patients undergoing repeat cardiac surgery reexposed to aprotinin .  
Antiaprotinin IgG and IgE antibody measurements, using an enzyme-
linked immunosorbent assay and an immunofluorescence assay, respectively, 
were performed preoperatively and postoperatively. This study found the 
incidence of anaphylactic reactions after aprotinin reexposure during cardiac 
surgery to be 2.5%. The propensity of a patient to react adversely to aprotinin 
treatment was highly dependent on the length of the aprotinin exposure–
reexposure interval.  
Davies et al 1997(8) 
They conducted a prospective, randomized, double-blind study of 
high-dose aprotinin in pediatric cardiac operations . Forty-two patients 
were randomly assigned to receive either high-dose aprotinin or placebo. 
Aprotinin efficacy was assessed using time from protamine 
administration to skin closure, postoperative blood loss and hemoglobin 
loss, and postoperative transfusion requirements. Measures of 
fibrinolysis (fibrin degradation product titers) and platelet preservation 
(b-thromboglobulin levels) were also assessed.  Results show that there 
were no statistically significant differences between groups in any of the 
blood loss or transfusion parameters.  
They concluded that aprotinin appears to provide no clinical 
benefit in routine pediatric cardiac operations. There were no differences 
in the drainage loss between controls and the aprotinin-treated groups. 
However, there was  statistically significant difference between surgical 
groups in drainage volume loss. The redo operation group, had a 
significantly lower drainage volume in the first 24 hours postoperatively. 
Reduction in fibrinolysis, with perhaps an early preservation of platelet 
structure, is seen in the aprotinin group.  
Van Oeveren et al 1987(12) 
They studied the effects of aprotinin on hemostatic mechanisms 
during cardiopulmonary  bypass. In this study , the protease inhibitor 
aprotinin was given in high doses to 11 patients to achieve plasma 
concentrations of more than 150 kallikrein inactivator units per milliliter 
during CPB. At such concentrations, kallikrein and plasmin are 
effectively inhibited. This treatment resulted in platelet preservation 
during CPB. Platelet numbers were virtually unaffected, and 
thromboxane release was prevented in the aprotinin-treated group in 
contrast to the control group. Postoperatively, hemostasis was 
significantly better preserved after aprotinin treatment (blood loss of 357 
ml in the treated group versus 674 ml in the untreated group; p less than 
0.01). Since tissue-plasminogen activator activity was similar in both 
groups, the improved hemostasis most likely should be attributed to 
platelet preservation. Furthermore, aprotinin lessened neutrophilic 
elastase release, which might contribute to decreased pulmonary 
dysfunction in patients at risk.  
Wong et al 2000(44) 
They compared the efficacy of aprotinin with tranexemic acid in 
reducing post operative blood loss for high risk cardiac surgery. 80 patients 
undergoing elective high transfusion risk cardiac procedures (repeat 
sternotomy, multiple valve, combined procedures, or aortic arch operation) 
were randomized in a double-blind fashion, to receive either high dose 
aprotinin or tranexamic acid. Patient and operative characteristics, chest tube 
drainage and transfusion requirements were recorded.  
They found that there was no significant difference between the 2 
treatment groups with respect to age, cardiopulmonary bypass time, 
complications (myocardial infarction, stroke, death), chest tube drainage (6, 12, 
or 24 hours), blood transfusions up to 24 hours postoperatively, total allogeneic 
blood transfusions for entire hospital stay, or induction/postoperative 
hemoglobin levels. However, multiple regression analysis revealed a positive 
relationship between cardiopulmonary bypass time and 24 hour blood loss in 
the tranexamic acid group (p = 0.001), unlike the aprotinin group where 24 hour 
blood loss is independent of cardiopulmonary bypass time (p = 0.423).  Overall, 
there was no significant difference in blood loss, or transfusion requirements, 
when patients received either aprotinin or tranexamic acid for high transfusion 
risk cardiac operation. Aprotinin, when given as an infusion in a high-dose 
regimen, was able to negate the usual positive effect of cardiopulmonary 
bypass time on chest tube blood loss. 
Blauhut et al 1991(32) 
They studied the effects of high-dose aprotinin on blood loss, platelet 
function, fibrinolysis, complement, and renal function after cardiopulmonary 
bypass. They  administered a mean aprotinin dose of 4.2 x 106 kallikrein-
inhibiting units to 13 patients with coronary disease undergoing 
cardiopulmonary bypass for 74 +/- 5 minutes (mean +/- standard error of the 
mean); 13 comparable patients having cardiopulmonary bypass served as 
control subjects, and all were studied postoperatively for 24 hours. 
Aprotinin reduced postoperative blood loss by 50% (p = 0.0082). Two of 
the 13 patients who received aprotinin needed one red cell unit each versus a 
total of 18 units in eight of 13 control patients (p = 0.0096). In control patients 
fibrinogen degradation products (D dimer) doubled, and alpha 2-antiplasmin 
activity was halved during and after cardiopulmonary bypass (p less than 0.01 
to p less than 0.001), whereas aprotinin patients showed no changes. Serum 
electrolytes, osmolality, and creatinine remained normal in both groups of 
patients. Creatinine clearance was normal or above normal and virtually 
identical                                                  in both groups.No adverse clinical 
effects attributable to aprotinin were seen. They concluded that aprotinin offers 
advantages for cardiopulmonary bypass. 
Harder et al 1991(41) 
To determine whether aprotinin can provide a significant 
improvement of hemostasis in cardiopulmonary bypass using a 
membrane oxygenator, they tested this drug in a prospective, 
randomized, double-blind, placebo- controlled clinical trial. The subjects 
were 80 male patients undergoing cardiopulmonary bypass for coronary 
artery bypass grafting. Forty patients received aprotinin and 40 patients 
served as placebo controls. Aprotinin (4 x 106 KIU) was given as a 
continuous infusion, starting before operation and continuing until after 
cardiopulmonary bypass; additionally, 2 x 106 KIU aprotinin was added 
to the pump prime. They concluded that aprotinin reduces intraoperative 
and postoperative blood loss in membrane oxygenator cardiopulmonary 
bypass. 
                                                                        
MATERIALS AND METHODS 
Study design 
This study was conducted in Paediatric Cardiothoracic Department 
at Institute of Child Health, an attached institution of Madras Medical 
College, Chennai between June 2008 and August 2008 on forty patients, 
posted for elective major cardiac surgery. This study was done after 
institutional approval and written informed consent was obtained from 
the parents of each child included in the study. 
This study was done in a prospective randomized manner. Forty 
patients of either sex posted for major elective cardiac surgeries 
satisfying the selection criteria were randomly allocated into the two 
groups (Group A and Group P) 
Group(A)- Patients in this group received  aprotinin 20000 KIU/kg 
bolus after induction, 20000 KIU/kg in prime and 
maintenance infusion dose of 10000 KIU/kg/min till 
skin closure.(14) 
Group(P)- Patients in this group received equal volume       
protocol of Ringer Lactate solution. 
SELECTION OF CASES 
Inclusion criteria 
Child under any age of less than 12 years undergoing open heart 
surgery using cardiopulmonary bypass (CPB) is considered eligible for 
entry into the study. 
Exclusion criteria 
• Patient refusal 
• Patients with known bleeding disorder; those taking aspirin, 
dipyridamole,or anticoagulants 7 days before surgery 
• Patients with a known metabolic disorder, sepsis, or renal 
failure 
• Patients previously exposed to aprotinin or with a known 
allergy to aprotinin 
• Patients with a hemoglobin level of more than 19 g/dl. 
Preanaesthetic evaluation 
Patients included in this study underwent thorough preoperative 
evaluation which included history, detailed physical examination and 
investigation. 
Patients who satisfied the selection criteria were explained about 
nature of the study and the anaesthetic procedure. Written informed 
consent was obtained from parents of each child. 
Two persons were required during the study. One was the operator 
(myself) who gave the drug. Second was the observer who recorded the 
parameters. All the parameters and events were observed and recorded in 
the proforma by the observer throughout the procedure.     
Pilot study 
The operator (myself) did a pilot study on 10 patients, who were 
selected based on above mentioned criteria, under expert guidance and 
supervision of senior anesthesiologists. Aprotinin was given to 5 patients 
and Ringer Lactate solution was given to 5 patients. After pilot study, 
the observations and results were analyzed in detail and based on safety 
profile, the institutional ethical committee approval was obtained for 
conducting the study. 
Anaesthetic procedure 
Each child’s weight and height was noted.  Standard monitoring 
for paediatric cardiac patients was done. Intravenous access with a 
cannula on right hand was achieved. Premedication, anesthetics, and 
perfusion techniques were similar for all patients. The patient was given 
IV fentanyl 2-5µg/kg, IV glycopyrrolate 10µg/kg, IV methyl 
prednisolone 30mg/kg, IV midazolam 0.15mg/kg was given. The patient 
was preoxygenated with 100% oxygen for 5 minutes. Induction of 
anesthesia used IV thiopentone sodium (2.5%) 5-7mg/kg, IV vecuronium 
bromide (0.1mg/kg) followed by intubation after 3 minutes of IPPV with 
100% oxygen. Under strict aseptic precautions, a central venous line and 
an arterial line were cannulated. Anaesthesia was maintained with 
nitrous oxide and oxygen (50:50) together with intermittent doses of 
vecuronium bromide 0.02 mg/kg, inhalational agent isoflurane at 1 MAC 
and incremental doses of IV fentanyl to a maximum of 20µg/kg or IV 
morphine to a maximum dose of 0.1 mg/kg, IV midazolam 
0.2mg/kg/hour. 
The patient was given test dose of aprotinin 10000 KIU 
intravenously after intubation and observed for 10 minutes for 
anaphylactic reactions and hemodynamic changes. After confirmation of 
no adverse reactions , loading dose of aprotinin 20000 KIU/kg was given 
as an intravenous bolus over 20 minutes, with a pump priming dose of 
20000 KIU/kg and a continuous infusion of 10000 KIU/kg/hour from the 
beginning of surgery until skin closure at the end of surgery. Group P 
patients were given an equivalent volume protocol of Ringer Lactate 
solution. 
The bypass machine was primed with a mixture of fresh (less than 
5 days old), whole citrate-phosphate-dextrose blood, mixed with 
crystalloid to achieve a predicted hematocrit of 25% to 30% in patients 
undergoing bypass. The crystalloid component of the prime was Ringer 
Lactate solution with added heparin (2,500 IU per unit of blood, and 
1,500IU per 500 ml of crystalloid), sodium bicarbonate (7.5% at 60 ml/l 
of prime), and 20%  mannitol (2 ml/kg). Perfusion techniques were 
standardized and the patient core temperature was lowered to the 
appropriate level using arteriovenous cooling on bypass. Flow rates were 
maintained at optimum levels not exceeding 2.4 litres per meter square 
per minute, using a nonpulsatile roller occlusive pump. The activated 
clotting time was serially measured every 30 minutes using Kaolin based 
ACT machine and values were maintained above 400 seconds for 
optimal heparinisation. Baseline ACT value was recorded  before 
administration of heparin. Ultrafiltration was not used. Before Aortic 
decannulation, heparin was reversed with protamine in the ratio of 1:1.3 
respectively under ACT monitoring, as per the Institutional protocol. 
Time from protamine administration to skin closure (minutes) was noted. 
Postoperative ACT value was calculated after 2 hours of skin closure. 
Perioperatively patients received prophylactic antibiotics(Cefotaxime) 
and cardiosupportive drugs (dopamine and nitroglycerin). After surgery, 
the patient was electively ventilated and extubated after adequate 
recovery. To standardize the blood transfusion regimen postoperatively, 
fresh blood was transfused to maintain the patient’s hematocrit at or 
more than 35%. 
Over the first 24 hours postoperatively, total chest drain blood loss 
(ml/kg), and total amount of fluid, blood and blood products given (ml) 
were measured. Blood samples were taken preoperatively and at the 
times given below to compare renal function (blood urea, serum levels of 
creatinine, sodium, bicarbonate and potassium) and hematologic 
functions (hemoglobin, hematocrit, white cell total count, differential 
count, platelet count, bleeding time, clotting time). Sequential blood 
samples were taken at the following times: 30 minutes before surgery, 6 
hours postoperatively and 24 hours postoperatively.                                 
Adverse events like anaphylaxis and renal dysfunction were 
recorded during this study. The anaphylactic reaction was defined as 
major changes from baseline within 10 minute of 10,000 KIU of test 
dose aprotinin administration, of systolic blood pressure 20 percent or 
greater, heart rate 20 percent or greater, inspiratory pressure greater than 
5cm of water or a skin reaction(33). Renal dysfunction was defined as 
postoperative creatinine of atleast 2mg/dl or an increase over 
preoperative baseline levels of atleast 0.7mg/dl.  
Parameters observed                                
1. The time interval (min) from protamine administration to skin 
closure. 
2. The volume of blood loss (ml/kg) in chest drain after 24 hours. 
3. The volume of blood and blood products (ml/kg) transfused 
postoperatively. 
4. The postoperative Activated Clotting Time (sec) after 2 hours of 
skin closure.  
5. The preoperative and postoperative bleeding time (sec). 
6. The preoperative and postoperative clotting time (sec). 
7. The preoperative, pump and postoperative platelet count 
(lakh/mm3). 
8. The preoperative, pump and postoperative haemoglobin (g/dl) 
9. The preoperative, pump and postoperative Packed Cell Volume 
(PCV%)  
10. Anaphylactic reactions  
11. Renal Dysfunction  
1. The time interval from protamine administration to skin 
closure:- 
The duration (minutes) between administration of total dose 
protamine and start of skin closure was noted. This includes mainly the 
duration of  adequate hemostasis and sternotomy closure. 
2. The volume of blood loss (ml/kg) in chest drain after 24 hours:- 
The volume of blood (ml/kg) after 24 hours in the chest drain was 
calculated by measuring the difference between the level (ml) of saline 
measured immediately after connecting the ICD tube to the drain and 
level (ml) at the end of 24 hours postoperatively. This measured  volume 
is divided by patient’s body weight (kg)  to get volume of blood loss in 
ml/kg.  
3. The volume of blood and blood products (ml/kg) transfused 
postoperatively:- 
The volume of blood and blood products(ml/kg) transfused            
postoperatively was calculated by measuring volume of blood and blood 
products (Fresh frozen plasma and platelets) transfused to the patient to 
maintain the Packed Cell Volume (PCV%) above 35% investigated at 
serial intervals. This measured  volume is divided by patient’s body 
weight (kg)  to get the volume of blood and blood products given in 
ml/kg.  
4. The postoperative Activated Clotting Time (sec) after 2 hours of 
skin closure:- 
The Activated Clotting Time (ACT) was measured after 2 hours of  
skin closure in postoperative ward using Kaolin based ACT catridge and 
Medtronic ACT II machine.  
5. The preoperative and postoperative bleeding  time (sec);- 
The bleeding time (sec) of the patient was measured preoperatively 
30 minutes  before surgery and postoperatively  24 hours after surgery.  
6. The preoperative and postoperative clotting time(sec):- 
The clotting time (sec) of the patient was measured   preoperatively    
30 minutes before surgery and postoperatively 24 hours after surgery. 
 
7. The preoperative, pump and postoperative platelet count 
(lakh/mm3):- 
The platelet count values (lakh/mm3 ) were investigated 
preoperatively  30 minutes before surgery, during cardiopulmonary 
bypass after  20 minutes start of the pump  and postoperatively 24 hours 
after surgery.  
8. The preoperative, pump and postoperative haemoglobin (g/dl):- 
The haemoglobin values (g/dl) were investigated  preoperatively  
30 minutes before surgery, during cardiopulmonary bypass after  20 
minutes start of the pump  and postoperatively 24 hours after surgery. 
9. The preoperative, pump and postoperative Packed Cell Volume 
(PCV%):- 
The Packed Cell Volume (PCV%) was investigated  preoperatively  
30 minutes before surgery, during cardiopulmonary bypass after  20 
minutes start of the pump  and postoperatively 24 hours after surgery. 
 
 
10. Anaphylactic reactions:- 
Patients were monitored for hemodynamic changes due to   
anaphylaxis to aprotinin given after induction. The anaphylactic reaction 
was defined as major changes from baseline within 10 minute of 10,000 
KIU of test dose aprotinin administration, of systolic blood pressure 20 
percent or greater, heart rate 20 percent or greater, inspiratory pressure 
greater than 5cm of water or a skin reaction(33). If anaphylactic reaction 
was present, it was recorded as (P) PRESENT, otherwise (A) ABSENT.  
11. Renal Dysfunction:- 
The preoperative and postoperative serum creatinine levels were 
investigated 30 min before surgery and 24 hour after surgery respectively. 
Renal dysfunction was defined as postoperative creatinine of atleast 2mg/dl or 
an increase over preoperative baseline levels of atleast 0.7mg/dl. If creatinine 
levels were elevated as per the above criteria, renal dysfunction was recorded  
as (P) PRESENT, otherwise (A) ABSENT. 
 
 
                                                      
 
OBSERVATIONS AND RESULTS 
 Forty children of either sex posted for major elective cardiac 
surgeries satisfying the selection criteria were randomly allocated into 
two groups. (Group A, Group P – 20 patients each) 
Group A:  Patients in this group received aprotinin 20000 KIU/kg 
bolus after induction, 20000 KIU/kg in prime and 
maintenance infusion dose of 10000KIU/kg/min till 
skin closure. 
Group P:   Patients in this group received equal volume protocol 
of Ringer Lactate solution. 
 
 
 
 
 
 
 
 
1.  Demographic profile 
 
Paramet
er 
Grou
p 
N Mea
n 
S.
D. 
‘t
’ test 
A 2
0 
7.15 2.9
7 
 
Age 
(years) 
P 2
0 
7.60 2.2
1 
 
p
= 0.591
A 2
0 
1.30 0.4
7 
 
Sex 
 P 2
0 
1.45 0.5
1 
 
p
= 0.340
A 2
0 
16.8
5 
4.3
0 Weight 
(kgs) P 2
0 
16.9
5 
4.1
1 
 
p
= 0.941
 
           The two groups were similar with respect to age, sex & 
weight 
 
  
 
 
 
 
 
2. The time interval (min) from protamine administration to skin 
closure 
 
Parameter Group N Mean S.D. ‘t’ test
Time 
interval (min) 
 
A 
 
20
 
31.45
 
6.08
 
p=0.000
from protamine 
administration to 
skin closure 
 
 
P 
 
20
 
52.05
 
8.71
 
 
         The mean time interval (min) from protamine administration 
to skin closure in                            
              Group A - 31.45 +/- 6.08 min 
              Group P - 52.05 +/- 8.71 min 
         There is significant reduction in duration of time from 
protamine administration to skin closure in group A. 
 
 
 
 
3. The volume of blood loss(ml/kg) in chest drain after 24 hours  
 
Parameter Group N Mean S.D. ‘t’ test
A 20 7.01 3.1324 hour 
drain blood loss 
 
P 20 8.72 3.09
       
p=0.090
 
The mean volume of blood loss (ml/kg) in chest drain after 24 hours in 
               Group A- 7.01 +/- 3.13 ml/kg 
               Group P – 8.72 +/- 3.09 ml/kg 
There is no significant reduction in volume of blood loss in chest drain in     
Group A. 
 
 
 
 
 
 
 
4. The volume of blood and blood products (ml/kg) transfused 
postoperatively  
 
Parameter Group N Mean S.D. ‘t’ test
A 20 8.36 5.49Blood and 
blood products 
given 
 
P 20 11.76 4.62 p=0.041
 
The mean volume of blood and blood products (ml/kg) transfused     
postoperatively in 
Group A - 8.36 +/- 5.49 ml/kg 
Group P - 11.76 +/- 4.62 ml/kg 
          There is significant reduction in volume of blood and blood 
products transfused postoperatively in Group A. 
 
 
  
 
 
 
5. The postoperative Activated Clotting time (ACT)  after 2 hours of 
skin closure  
 
Paramet
er 
Grou
p 
N Mea
n 
S.D. ‘t
’ test 
     A 2
0 
132.4
0 
15.5
0 
ACT 
after 2 hours of 
skin closure 
(sec) 
P 2
0 
137.5
0 
12.1
5 
 
p
= 0.254
 
              The postoperative Activated Clotting Time after 2 hours 
of skin closure in Group A (132.4 +/- 15.50) when compared to Group P 
(137.5 0 +/- 12.15) was found to be statistically insignificant. 
 
 
 
 
 
 
 
 
 
 
6. The preoperative and postoperative bleeding time  
 
Parame Gro n Mea S.D ‘t’ 
ter up n . test 
A 2
0 
141.
50 
24.
60 Bleedin
g time     
preop P 2
0 
150.
25 
34.
16 
p= 
0.359 
A 2
0 
147.
25 
30.
88 
Bleedin
g time postop 
P 2
0 
174.
00 
45.
09 
p=0.
35 
 
           There is no statistical significance in preoperative and 
postoperative bleeding time between the two groups. 
 
 
 
  
 
 
 
 
7. The preoperative and postoperative clotting time (sec) 
 
Paramet
er 
Grou
p 
n Mea
n 
S.D. ‘t
’ test 
A 2
0 
296.5
0 
32.4
0 Clotting 
time 
Preop P 2
0 
269.8
5 
30.8
2 
p 
=0.011
A 2
0 
326.0
0 
30.3
7 
Clotting 
time 
Postop 
P 2
0 
320.2
5 
29.1
7 
p 
=0.545
 
             There is no statistical significance in preoperative and 
postoperative clotting time between the two groups 
 
 
 
 
 
 
 
 
8. The preoperative, pump and postoperative platelet count      
(lakh/mm3 ) 
 
Parame
ter 
Gro
up 
N Me
an 
S.
D. 
‘t’ 
test 
A 2
0 
3.14 0.
67 
Platelet  
count 
preop 
P 2
0 
2.94 0.
72 
p=0.3
69 
A 2
0 
1.33 0.
17 
Platelet 
count 
Pump 
P 2
0 
1.12 0.
23 
p=0.0
03 
Platelet 
count 
A 2
0 
2.08 0.
32 
p=0.1
15 
Postop 
P 2
0 
2.27 0.
40 
 
 
            There is statistical significance in platelet count during 
pump time between the two groups. The preoperative and postoperative 
platelet count values were found to be insignificant between the two 
groups. 
 
 
 
 
9. The preoperative, pump and postoperative haemoglobin (g/dl) 
 
Parame
ter 
Gro
up 
N Me
an 
S.
D. 
‘t’ 
test 
A 2
0 
11.8
8 
1.
29 
 
Hb 
preop 
P 2
0 
12.1
4 
1.
22 
p=0.5
18 
A 2
0 
8.90 0.
77 
 
Hb 
pump 
P 2
0 
8.74 0.
62 
p=0.4
62 
A 2
0 
13.2
4 
1.
29 
 
Hb 
postop 
P 2
0 
12.7
4 
1.
14 
p=0.2
04 
 
            There is no statistical significance in preoperative, pump 
and postoperative hemoglobin values between the two groups 
  
 
 
 
 
 
10.  The preoperative, pump and postoperative packed cell volume 
(PCV) 
 
Parame
ter 
Gro
up 
N Me
an 
S.
D. 
‘t’ 
test 
A 2
0 
37.3
9 
3.
04 
 
PCV 
preop 
P 2
0 
37.7
4 
3.
26 
 
p=0.7
32 
A 2
0 
27.5
5 
2.
48 
 
PCV 
pump 
P 2
0 
28.2
0 
1.
80 
 
p=0.3
50 
A 2
0 
40.1
8 
3.
27 
 
PCV 
postop 
P 2
0 
39.4
6 
3.
81 
 
p=0.5
26 
 
            There is no statistical significance in preoperative, pump 
and postoperative packed cell volume (PCV%) values between the two 
groups. 
 
 
 
11. Anaphylactic reactions 
Observations showed none of the patients in both the groups had 
anaphylactic reactions. The results were statistically insignificant 
between the groups. 
12. Renal Dysfunction 
Observations showed none of the patients in both the groups had 
elevated serum creatinine levels and renal dysfunction postoperatively. 
The results were statistically insignificant between the groups. 
 
 
DISCUSSION 
The observations and results showed a clear benefit in reducing the 
duration of surgical procedure and transfusion of blood and blood 
products in routine paediatric open heart surgeries using 
cardiopulmonary bypass. These findings  were similar to the results of 
previously published studies and meta-analysis of randomized controlled 
studies done on evaluation of efficacy of aprotinin in paediatric cardiac 
surgery . 
Demographic profile 
Many prospective randomized controlled studies were conducted to 
evaluate the hemostatic benefits of aprotinin in paediatric open heart 
surgeries: Mossinger et al 2003(21) ,Miller et al 1998(4) , Davies et al 
1997(8),  Harder et al 1991(41). 
The present study included the paediatric patients posted for major 
open heart surgeries like atrial septal defect closure, ventricular septal 
defects closure . This clinical setting was chosen based on periods of 
hands on training under expert guidance. Furthermore, this controlled 
environment of paediatric cardiothoracic vascular theatre and 
postoperative Intensive Care Unit(ICU) provided excellent facilities and 
safety features for conduct of the study. In the present study, both the 
groups were similar with respect to age, sex and weight.   
The time interval (min) from protamine administration to skin 
closure  
In Miller et al 1998(4) study, the mean time interval from protamine 
administration to skin closure in control group is 88 +/- 41minutes, in 
low dose group is 64 +/- 22 minutes and high-dose group is 56 +/-16 
minutes.  Results were found to be significant in aprotinin groups. 
In the present study, the mean time interval from protamine 
administration to skin closure in Group A is 31.45 +/-  6.08 minutes and Group 
P is 52.05 +/-  8.71 minutes. There is significant reduction in duration of time  
from protamine administration to skin closure in  
group A. 
The volume of blood loss (ml/kg) in chest drain after 24 hours 
In Miller et al 1998(4) study, there was no significant difference in 
chest tube drainage between groups at 6 hours (control, 13.0 +/- 8.6 
ml/kg; low-dose, 14.1 +/- 6.8 ml/kg; and high-dose, 16.3 +/- 14.5 ml/kg) 
or 24 hours (control, 28.9 +/- 17.2 ml/kg; low-dose, 31.6 +/- 23.1 ml/kg; 
and high-dose, 36.0 +/- 26.4 ml/kg) postoperatively. 
In the present study, the mean volume of blood loss (ml/kg) in chest 
drain after 24 hours in Group A  is 7.01 +/- 3.13 ml/kg and  Group P is 8.72 +/- 
3.09 ml/kg. In this study also there is no significant difference  in chest tube 
drainage between groups at 24 hours. 
The volume of blood and blood products(ml/kg) transfused 
postoperatively 
In Royston et al 1987(42) study, out of 22 patients undergoing 
repeat open-heart surgery ,11 were randomised to receive aprotinin. 
Their mean blood loss was 286 ml compared with 1509 ml in the 11 
control patients (p <0.001). Blood transfusion requirements were 
eightfold higher in the control group than in the aprotinin group, 7 of 
whom received only the single unit of their own blood taken before 
cardiopulmonary bypass. 
In the present study, the mean volume of whole blood (ml/kg) transfused 
postoperatively in Group A is 8.36 +/-  5.49 ml/kg and Group P is 11.76 +/-  
4.62 ml/kg. There is significant reduction in volume of blood  and blood 
products transfused postoperatively in Group A. 
The postoperative Activated Clotting time (ACT) after 2 hours of skin 
closure 
There is no statistical difference in ACT values calculated after 2 hours 
of skin closure between the two groups. 
 The preoperative and postoperative bleeding time (sec) 
There is no statistical significance in preoperative and 
postoperative bleeding time between the two groups. 
The preoperative and postoperative bleeding and clotting time 
(sec) 
There is no statistical significance in preoperative and 
postoperative clotting time between the two groups. 
The preoperative, pump and postoperative platelet count 
(lakh/mm3 ) 
There is statistical significance in the platelet count during pump 
time between the two groups . The preoperative and postoperative 
platelet count values were found to be insignificant between the two 
groups. 
Anaphylactic reactions 
In Davies et al 1997(8) study, there were no episodes of anaphylaxis in 
any of the patients who received aprotinin.    
In the present study, observations showed none of the patients in 
both the groups had anaphylactic reactions. The results were statistically 
insignificant between the two groups. 
 Renal Dysfunction 
In Davies et al 1997(8) study, there were no episodes of renal 
dysfunction observed in any of the patients who received aprotinin. 
In the present study, observations showed none of the patients  in 
both the groups had elevated serum creatinine levels and renal 
dysfunction postoperatively. The results were statistically insignificant 
between the two groups. 
 
                                                         
SUMMARY 
In this study the efficacy and use of aprotinin in paediatric cardiac 
surgery was assessed based on following parameters: 
1. The time interval (min) from protamine administration to skin 
closure. 
2. The volume of blood loss (ml/kg) in chest drain after 24 hours. 
3. The volume of blood and blood products (ml/kg) transfused           
postoperatively. 
1. The mean time interval (min) from protamine administration to skin 
closure in 
Group A - 31.45 +/- 6.08 min 
Group P - 52.05 +/- 8.71 min 
There is significant reduction in duration of time from protamine        
administration to skin closure in group A. 
2. The mean volume of blood loss (ml/kg) in chest drain after 24 hours in 
 
Group A- 7.01 +/- 3.13 ml/kg 
Group P – 8.72 +/- 3.09 ml/kg 
There is no significant reduction in volume of blood loss in chest 
drain in Group A. 
3. The mean volume of blood and blood products (ml/kg) transfused       
postoperatively in 
Group A - 8.36 +/- 5.49 ml/kg 
Group P - 11.76 +/- 4.62 ml/kg 
There is significant reduction in volume of blood and blood 
products transfused postoperatively in Group A. 
 
 
             
 
  
 
  
 
 
CONCLUSION 
From this study, it is observed that in children undergoing open heart 
surgery using cardiopulmonary bypass, aprotinin is effective in improving 
clinical outcomes of the patients, by reducing postoperative blood transfusion 
requirements and duration of the surgery. There is a decreased requirement of 
banked blood and donor exposures. Aprotinin recipients have a significantly 
dry operative field after protamine reversal, aiding in early hemostasis and skin 
closure, thereby it shortens the duration of surgical procedure. Hence it is 
concluded that aprotinin is useful in anaesthetic management of the children 
undergoing open heart surgery. 
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PROFORMA 
Name     : 
Age     : 
Sex     : 
Height    : 
Weight     : 
ASA     : 
Study Group    : 
Informed consent   : 
Hospital No    : 
Date     : 
Diagnosis    : 
Operative procedure  : 
Co morbid illness   : 
General Examination   : 
            PR - 
 BP - 
 CVS - 
 RS - 
            GIT - 
            CNS - 
            Airway - MPC 
    
Preop:- 
Hb   -        
PCV   - 
TC   -              DC-P   % L    %E   %    ESR: 
Platelet count  -                               
Blood Urea  -                  
Blood Sugar  - 
Serum Creatinine - 
Electrolytes in meq- Na         K      HCO3 
Inj.Glycopyrrolate-                   (10µg/kg) 
Inj.Midazolam-                        (0.15mg/kg)  
Inj.Fentanyl-                            (2-5µg/kg) 
Inj.Methyl prednisolone-         (30mg/kg) 
 
Induction:- 
Inj.Thiopentone sodium-           (5µg/kg) 
Inj.Vecuronium bromide-          (0.1mg/kg)  
 
Maintenance:- 
O2(50%)/N2O(50%) 
Inj.Vecuronium bromide-         (0.02mg/kg/30min) 
Inj.Fentanyl -                            (maximum of 20µg/kg) 
Inj.Morphine-                           (maximum of 0.1 mg/kg) 
Inj.Midazolam-                        (0.2mg/kg/hour)  
     
Intraop:- 
Group (A)-  
Aprotinin dose    
          After induction-                               (20,000KIU/kg) 
          Pump prime-                                      (20,000KIU/kg) 
          Maintenance-                                   (10,000KIU/kg/hr) 
Group(P)- 
Equal volume of Ringer Lactate solution 
         After induction- 
         Pump prime-                                       
         Maintenance-  
Total heparin dose- 
Baseline ACT- 
Total protamine dose- 
Protamine time- 
Skin closure time- 
 
Introperative Hemodynamics:- 
 
Time HR(min) BP(mmHg) SPO2% 
ACT-
1/2 
hourly(secs)
0 
Min 
    
1 
Min 
    
2 
Min 
    
3 
Min 
    
4 
Min 
    
5 
Min 
    
10 
Min 
    
15 
Min 
    
20 
Min 
    
25 
Min 
    
30 
Min 
    
35 
Min 
    
40 
Min 
    
45 
Min 
    
50 Min 
    
55 
Min 
    
60 
Min 
    
  till 
end of 
surgery 
    
     
     
     
 
Hb   -                                       
PCV   - 
Platelet Count  -                       
Blood transfused -                            
Intravenous fluids -                
Total urine output - 
Anaphylaxis  -  ABSENT(A)/PRESENT(P) 
 
 
 
 
 
Post op:- 
 T
ime b 
P
CV 
P
latelet 
Count 
B
lood 
Sugar 
S
.Urea 
S.C N
a+ + 
H
CO3- 
6
hours 
      
2
4hours 
      
 
TC-              DC-  P    %, L     %, E    %, ESR:         
ACT (2 hours after skin closure)- 
Renal dysfunction- ABSENT(A)/PRESENT(P) 
Blood and blood products transfused-                         
24 hour total intravenous fluids- 
24 hour chest drain blood loss-  
24 hour urine output- 
 
 
 
  
 
 
 
 
 
S.No I.P.NO AGE (yrs)
SEX 
(M/F)
Wt 
(kgs)
PROTAMINE 
TO SKIN 
CLOSURE 
TIME (min)
24 HOUR 
DRAIN 
BLOOD 
LOSS(ml/kg)
BLOOD 
PRODUCT
S GIVEN 
(ml/kg)
ANAPH
YLAXIS
RENAL 
DYSFUN
CTION
Group P BASELINE 2 Hours PREOP POSTOP PREOP POSTOP PREOP PUMP POSTOP PREOP PUMP POSTOP PREOP PUMP POSTOP
1 611909 9 F 17 45 8.82 5.88 103 134 3:00 4:10 5:20 5:50 2.30 1.40 1.80 11.80 9.80 12.20 35.00 28.00 44.70 A A
2 613987 5 F 12 48 6.66 4.17 145 160 2:45 3:15 4:55 4:30 2.90 1.00 1.60 12.40 8.90 15.10 39.00 28.00 45.00 A A
3 615621 6 F 14 55 7.14 16.07 110 140 2:45 5:00 4:00 5:50 1.70 1.10 2.50 12.90 8.50 13.20 40.00 27.50 47.00 A A
4 616069 7 M 20 62 7.50 10.00 123 136 3:15 3:10 4:00 5:50 3.40 0.90 2.30 11.70 8.20 13.20 35.00 26.00 40.00 A A
5 615655 5 M 14 52 3.57 14.29 113 132 2:15 2:45 4:10 6:10 3.10 1.10 2.35 11.32 9.30 13.00 35.30 29.00 40.00 A A
6 615326 10 M 18 38 13.88 13.89 128 128 2:50 3:15 5:00 5:15 3.60 1.00 2.40 10.80 8.20 13.40 38.00 28.00 40.00 A A
7 610093 9 M 14 44 12.86 14.29 114 135 2:15 2:50 4:15 5:30 3.73 0.90 2.10 15.00 9.40 12.20 43.60 30.00 36.00 A A
8 614891 5 M 12 58 8.33 12.50 123 125 1:05 2:00 5:20 5:00 2.60 1.30 2.20 14.40 8.10 11.20 44.00 26.00 34.00 A A
9 618523 5 M 13 45 7.69 11.54 100 140 1:45 2:15 4:02 5:10 4.10 1.10 2.40 13.20 8.80 11.50 40.00 28.00 35.30 A A
10 617845 6 F 15 40 8.00 10.00 132 160 2:00 2:20 3:50 5:05 3.82 1.20 1.90 10.80 8.00 11.40 35.00 26.30 35.00 A A
11 615431 6 F 13 65 10.77 13.85 102 122 2:15 3:15 4:20 4:50 2.60 1.30 1.90 11.60 9.40 13.20 36.00 30.00 38.20 A A
12 617530 10 F 20 42 9.00 15.00 98 134 2:45 3:15 5:10 5:50 1.70 1.00 2.30 12.00 8.30 14.00 38.00 28.00 40.30 A A
13 616876 8 M 19 55 7.87 18.42 114 155 2:50 3:10 4:45 5:10 2.30 1.10 2.60 12.40 9.20 11.40 38.30 29.00 36.00 A A
14 617518 11 F 25 62 9.20 14.00 130 143 2:55 2:00 3:50 5:00 3.20 1.50 2.90 13.30 9.60 14.20 42.00 32.00 42.30 A A
15 615164 11 M 24 62 6.25 10.41 102 132 2:45 3:00 4:10 5:10 3.30 1.30 2.60 11.80 8.40 11.20 35.20 28.00 35.80 A A
16 618154 5 F 14 50 7.14 5.55 99 128 1:50 2:30 5:00 5:30 2.40 1.00 1.90 10.40 8.00 12.20 33.00 26.00 35.40 A A
17 614892 9 F 24 48 6.25 4.16 119 143 2:10 2:20 5:00 6:10 2.80 1.20 2.10 13.20 9.40 13.50 41.00 32.00 42.00 A A
18 618298 6 M 15 65 17.33 20.00 93 118 2:50 2:20 4:30 5:15 4.10 1.00 3.20 11.80 8.10 14.00 38.00 27.30 44.00 A A
19 618156 10 M 20 45 10.00 15.00 107 155 2:20 2:00 4:20 5:10 3.10 1.20 2.60 11.60 9.20 13.20 35.40 29.00 40.20 A A
20 610604 9 M 16 60 6.25 6.25 116 130 3:30 3:10 4:00 4:30 2.20 0.90 1.80 10.50 8.00 11.50 33.00 26.00 38.00 A A
Group A
1 610097 9 M 20 25 4.00 7.50 110 130 2:20 2:00 3:45 4:20 4.10 1.10 1.90 11.70 9.20 13.50 35.00 27.00 42.00 A A
2 611410 6 M 15 30 3.33 3.33 89 110 2:20 2:15 4:15 4:45 4.10 1.40 2.20 11.60 8.40 13.00 35.20 25.00 41.10 A A
3 611890 5 M 10 27 10.00 15.00 113 126 1:30 1:45 4:45 5:15 3.10 1.30 1.70 10.90 8.40 11.80 35.00 25.00 36.00 A A
4 611220 2 F 10 30 11.00 12.50 112 125 2:15 2:30 4:00 5:10 4.05 1.29 2.30 11.30 10.80 10.80 35.40 29.00 38.00 A A
5 610684 11 M 20 35 2.50 7.50 109 121 2:10 2:30 5:15 6:10 2.80 1.30 2.10 9.60 8.20 14.70 36.00 26.00 41.00 A A
6 613537 5 M 13 25 4.23 7.69 87 103 2:15 2:00 5:30 6:10 3.48 1.10 2.30 10.80 8.00 11.80 33.70 26.00 37.00 A A
7 614221 10 F 20 32 5.00 10.00 101 122 2:10 2:30 4:30 5:25 2.60 2.00 2.73 12.80 8.80 14.90 40.00 28.00 44.90 A A
8 606658 9 F 20 30 5.75 7.50 112 136 2:05 2:15 5:00 5:30 2.20 1.00 2.10 12.00 9.00 11.80 40.00 27.00 37.00 A A
9 608351 9 M 15 30 10.00 0.00 135 160 1:50 2:00 5:45 6:00 1.92 1.60 1.80 13.50 9.80 14.80 40.40 35.00 41.40 A A
10 609640 5 M 15 33 8.33 6.66 123 154 2:35 1:45 5:30 5:10 2.30 1.40 1.57 11.20 8.40 11.40 42.00 26.20 37.00 A A
11 610794 4 F 16 25 9.37 9.38 109 137 1:50 2:10 4:45 5:10 3.12 1.30 1.80 13.10 8.80 14.00 40.30 25.00 42.00 A A
12 604158 2 M 10 45 12.50 20.00 124 145 2:00 1:45 5:10 5:15 2.75 1.34 2.10 12.20 10.00 12.20 40.80 30.00 34.00 A A
13 609352 10 M 20 35 10.00 5.00 140 154 2:20 2:30 5:15 5:30 2.39 1.40 2.40 15.10 10.30 14.30 43.10 32.00 42.00 A A
14 610984 11 M 25 34 3.20 2.00 133 138 2:55 3:00 4:45 5:15 3.10 0.95 1.73 10.80 8.00 14.50 34.00 26.00 45.00 A A
15 612593 5 M 15 32 8.00 10.00 139 155 2:30 2:45 5:15 6:00 3.10 1.50 1.60 11.10 8.50 12.10 33.00 27.00 35.00 A A
16 614692 9 M 24 38 6.25 0.00 112 123 3:00 3:30 4:45 5:15 4.20 1.40 2.45 12.90 9.20 14.50 38.00 28.00 44.10 A A
17 611417 6 M 16 40 8.75 18.75 109 130 2:50 3:10 4:45 5:00 3.20 1.40 2.36 12.00 8.70 13.50 36.70 28.40 40.10 A A
18 611876 7 F 15 20 10.00 13.33 112 124 2:30 2:55 4:50 5:10 3.83 1.10 1.90 12.70 8.40 13.10 37.30 26.40 41.00 A A
19 610195 6 M 18 38 5.55 6.11 97 117 2:45 2:40 5:25 6:00 3.34 1.20 2.40 12.60 8.80 14.40 38.00 26.10 43.00 A A
20 612595 12 F 20 25 2.50 5.00 132 138 3:00 3:10 5:40 6:10 3.30 1.60 2.30 9.80 8.40 13.70 34.00 28.00 42.00 A A
ACT(Sec) PCV %BLEEDING TIME (min:sec)
CLOTTING TIME 
(min:sec)
PLATLET COUNT 
(lakh/mm3)
Hb g/dl
